Cargando…

(18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy

SIMPLE SUMMARY: In breast cancer (BC) patients, neoadjuvant chemotherapy (NAC) is chemotherapy given before surgery. Complete pathological response (pCR) to NAC is defined as the absence of residual tumor cells on microscopy both in the breast and in the axillary or distant lymph nodes in the surgic...

Descripción completa

Detalles Bibliográficos
Autores principales: Quartuccio, Natale, Alongi, Pierpaolo, Urso, Luca, Ortolan, Naima, Borgia, Francesca, Bartolomei, Mirco, Arnone, Gaspare, Evangelista, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216747/
https://www.ncbi.nlm.nih.gov/pubmed/37345052
http://dx.doi.org/10.3390/cancers15102715
_version_ 1785048372225245184
author Quartuccio, Natale
Alongi, Pierpaolo
Urso, Luca
Ortolan, Naima
Borgia, Francesca
Bartolomei, Mirco
Arnone, Gaspare
Evangelista, Laura
author_facet Quartuccio, Natale
Alongi, Pierpaolo
Urso, Luca
Ortolan, Naima
Borgia, Francesca
Bartolomei, Mirco
Arnone, Gaspare
Evangelista, Laura
author_sort Quartuccio, Natale
collection PubMed
description SIMPLE SUMMARY: In breast cancer (BC) patients, neoadjuvant chemotherapy (NAC) is chemotherapy given before surgery. Complete pathological response (pCR) to NAC is defined as the absence of residual tumor cells on microscopy both in the breast and in the axillary or distant lymph nodes in the surgical specimen. Achievement of pCR is associated with longer disease-free survival (DFS), namely survival without tumor recurrence. [(18)F]Fluorodeoxyglucose ((18)F-FDG) positron emission tomography may represent a complementary imaging tool in predicting pCR to NAC. We found (PET)-derived parameters predicting DFS in patients with BC with different molecular subtypes (based on the presence of specific receptors in the tumor). Furthermore, we demonstrated that some of these parameters predicting DFS are significantly different in patients achieving pCR compared to those without pCR after NAC. Larger study samples are needed to confirm these preliminary findings. ABSTRACT: We investigated whether baseline [(18)F] Fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)-derived semiquantitative parameters could predict disease-free survival (DFS) in patients with grade III breast cancer (BC) of different molecular subtypes candidate to neoadjuvant chemotherapy (NAC). For each (18)F-FDG-PET/CT scan, the following parameters were calculated in the primary tumor (SUVmax, SUVmean, MTV, TLG) and whole-body (WB_SUVmax, WB_MTV, and WB_TLG). Receiver operating characteristic (ROC) analysis was used to determine the capability to predict DFS and find the optimal threshold for each parameter. Ninety-five grade III breast cancer patients with different molecular types were retrieved from the databases of the University Hospital of Padua and the University Hospital of Ferrara (luminal A: 5; luminal B: 34; luminal B-HER2: 22; HER2-enriched: 7; triple-negative: 27). In luminal B patients, WB_MTV (AUC: 0.75; best cut-off: WB_MTV > 195.33; SS: 55.56%, SP: 100%; p = 0.002) and WB_TLG (AUC: 0.73; best cut-off: WB_TLG > 1066.21; SS: 55.56%, SP: 100%; p = 0.05) were the best predictors of DFS. In luminal B-HER2 patients, WB_SUVmax was the only predictor of DFS (AUC: 0.857; best cut-off: WB_SUVmax > 13.12; SS: 100%; SP: 71.43%; p < 0.001). No parameter significantly affected the prediction of DFS in patients with grade III triple-negative BC. Volume-based parameters, extracted from baseline (18)F-FDG PET, seem promising in predicting recurrence in patients with grade III luminal B and luminal B- HER2 breast cancer undergoing NAC.
format Online
Article
Text
id pubmed-10216747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102167472023-05-27 (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy Quartuccio, Natale Alongi, Pierpaolo Urso, Luca Ortolan, Naima Borgia, Francesca Bartolomei, Mirco Arnone, Gaspare Evangelista, Laura Cancers (Basel) Article SIMPLE SUMMARY: In breast cancer (BC) patients, neoadjuvant chemotherapy (NAC) is chemotherapy given before surgery. Complete pathological response (pCR) to NAC is defined as the absence of residual tumor cells on microscopy both in the breast and in the axillary or distant lymph nodes in the surgical specimen. Achievement of pCR is associated with longer disease-free survival (DFS), namely survival without tumor recurrence. [(18)F]Fluorodeoxyglucose ((18)F-FDG) positron emission tomography may represent a complementary imaging tool in predicting pCR to NAC. We found (PET)-derived parameters predicting DFS in patients with BC with different molecular subtypes (based on the presence of specific receptors in the tumor). Furthermore, we demonstrated that some of these parameters predicting DFS are significantly different in patients achieving pCR compared to those without pCR after NAC. Larger study samples are needed to confirm these preliminary findings. ABSTRACT: We investigated whether baseline [(18)F] Fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)-derived semiquantitative parameters could predict disease-free survival (DFS) in patients with grade III breast cancer (BC) of different molecular subtypes candidate to neoadjuvant chemotherapy (NAC). For each (18)F-FDG-PET/CT scan, the following parameters were calculated in the primary tumor (SUVmax, SUVmean, MTV, TLG) and whole-body (WB_SUVmax, WB_MTV, and WB_TLG). Receiver operating characteristic (ROC) analysis was used to determine the capability to predict DFS and find the optimal threshold for each parameter. Ninety-five grade III breast cancer patients with different molecular types were retrieved from the databases of the University Hospital of Padua and the University Hospital of Ferrara (luminal A: 5; luminal B: 34; luminal B-HER2: 22; HER2-enriched: 7; triple-negative: 27). In luminal B patients, WB_MTV (AUC: 0.75; best cut-off: WB_MTV > 195.33; SS: 55.56%, SP: 100%; p = 0.002) and WB_TLG (AUC: 0.73; best cut-off: WB_TLG > 1066.21; SS: 55.56%, SP: 100%; p = 0.05) were the best predictors of DFS. In luminal B-HER2 patients, WB_SUVmax was the only predictor of DFS (AUC: 0.857; best cut-off: WB_SUVmax > 13.12; SS: 100%; SP: 71.43%; p < 0.001). No parameter significantly affected the prediction of DFS in patients with grade III triple-negative BC. Volume-based parameters, extracted from baseline (18)F-FDG PET, seem promising in predicting recurrence in patients with grade III luminal B and luminal B- HER2 breast cancer undergoing NAC. MDPI 2023-05-11 /pmc/articles/PMC10216747/ /pubmed/37345052 http://dx.doi.org/10.3390/cancers15102715 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Quartuccio, Natale
Alongi, Pierpaolo
Urso, Luca
Ortolan, Naima
Borgia, Francesca
Bartolomei, Mirco
Arnone, Gaspare
Evangelista, Laura
(18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title_full (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title_fullStr (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title_full_unstemmed (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title_short (18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
title_sort (18)f-fdg pet-derived volume-based parameters to predict disease-free survival in patients with grade iii breast cancer of different molecular subtypes candidates to neoadjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216747/
https://www.ncbi.nlm.nih.gov/pubmed/37345052
http://dx.doi.org/10.3390/cancers15102715
work_keys_str_mv AT quartuccionatale 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT alongipierpaolo 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT ursoluca 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT ortolannaima 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT borgiafrancesca 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT bartolomeimirco 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT arnonegaspare 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy
AT evangelistalaura 18ffdgpetderivedvolumebasedparameterstopredictdiseasefreesurvivalinpatientswithgradeiiibreastcancerofdifferentmolecularsubtypescandidatestoneoadjuvantchemotherapy